JP Patent

JP5385139B2 — トリアゾロ［４，５−ｄ］ピリミジン誘導体を含んでなる経口投与に適した組成物

Assigned to AstraZeneca AB · Expires 2014-01-08 · 12y expired

What this patent protects

Patent listed against Brilinta.

Drugs covered by this patent

Patent Metadata

Patent number
JP5385139B2
Jurisdiction
JP
Classification
—
Expires
2014-01-08
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.